Allarity Therapeutics, Inc.

BOSTON, MA · Founded 2021 · Biotech · Public

Drug Response Predictor (DRP) technology and companion oncology therapeutics for precision cancer treatment

Claim this profile

Follows are private to you and power your alerts

Updated · allarity.com

Sector
Biotech
Headquarters
BOSTON, MA
Founded
2021
Latest Form D
$400K, Feb 2024
Total capital
$26.9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$26.9M
6 Form D · last Feb 2024
33 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
2 pending

Capital timeline

2021202220232024FEDERAL ↑EQUITY ↓Cumulative $26.9M1st Form D$20M2nd Form D$1.2M3rd Form D$350K4th Form D$3.4M5th Form D$1.6M6th Form D$400K

Latest events

  • Private capital raisedForm D · SEC · 6th filing$400K
  • Private capital raisedForm D · SEC · 5th filing$1.6M
  • Private capital raisedForm D · SEC · 4th filing$3.4M
  • Private capital raisedForm D · SEC · 3rd filing$350K
  • Private capital raisedForm D · SEC · 2nd filing$1.2M
  • Private capital raisedForm D · SEC · 1st filing$20M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders & Team

From Form D filings · 11 related persons
  • Laura BenjaminDirector
  • Joan BrownExecutive Officer
  • Steve CarchediDirector · Executive Officer
  • James CullemDirector · Executive Officer
  • Marie FoeghExecutive Officer
  • Thomas JensenDirector · Executive Officer
  • Jens KnudsenExecutive Officer
  • Steen KnudsenExecutive Officer
Show all 11 people
  • Gerald McLaughlinDirector
  • David RothDirector
  • Joseph VazzanoDirector

Patents

USPTO · 0 granted of 2
  • Methods For Treating Cancerapplication
  • Methods For Treating Cancerapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.